Novartis Ag

Other

Sandoz Gmbh

Novartis Ag (formerly Sandoz Ltd.)

Novartis Pharma Gmbh

Eberhard Bau Ag

Rainer Albert

Wilfried Bauer

Christian Bruns

Claus Ehrhardt

Gisbert Weckbecker

Janos Pless

Ian Lewis

Richard Sedrani

Bernhard Wietfeld

Peter Von Matt

Sylvain Cottens

Nigel Graham Cooke

Gerhard Zenke

David Bodmer

Mark Meisenbach

Jean-Pierre Evenou

Heribert Hellstern

Ivo Felner

Frederic Zecri

Klaus Hinterding

Sompong Wattanasin

Eric Francotte

Eric Paul Krenning

Gabriele Weitz-Schmidt

Steven W Lamberts

Markus Zollinger

Karl Welzenbach

Barbara Stolz

Peter Smith-Jones

Gebhard Thoma

Jürgen Wagner

Peter Ettmayer

Josef Gottfried Meingassner

Sven Weiler

Joerg Kallen

Ulrich Hommel

Peter Nussbaumer

Frédéric Zecri

Francois Cardinaux

Klemens Högenauer

Markus Streiff

Volker Brinkmann

Hans-Günter Zerwes

Monika Mergler

Christos Papageorgiou

Walter Prikoszovich

Francedillaois Cardinaux

Janet Dawson

Barbara Nuesslein-Hildesheim

Helmut Macke

François Nuninger

Nagarajan Chandramouli

Thomas Baumruker

Eva Erika Prieschl-Strassmayr

Didier Roche

J&uuml;rgen Wagner

The invention provides cyclo[{4-(NH&#x2014;CH&#x2014;NH&#x2014;CO&#x2014;O&#x2014;)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.

Somatostatin analogues

The invention provides cyclo[{4-(NH&#x2014;CH&#x2014;NH&#x2014;CO&#x2014;O-)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.

Compounds of formula I: wherein R, R, n and m are as defined in the specification, processes for their production, their uses and pharmaceutical compositions containing them.

Aminopropanol derivatives

Compounds of formula I, wherein X, a, b, R, R, R, Rand Rare as defined in the specification, processes for their production, their uses and pharmaceutical compositions containing them.

Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators

Indolylmaleimide derivatives comprising either a substituted phenyl, naphthyl, tetrahydronaphthyl, quinazolinyl, quinolyl, isoquinolyl or pyrimidinyl residue have interesting pharmaceutical properties, e.g. in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection or cancer.

Indolylmaleimide derivatives

The present invention relates to polycyclic compounds, processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

Reverse isoxazoles

Disclosed are compounds of formula I: wherein R, R, Rand X are as defined herein, in free or salt form, which are useful as CCR5 inhibitors, e.g. in the prevention or treatment of disorders mediated by interactions between chemokine receptors and their ligands.

Piperidine derivatives as CCR5 inhibitors

Compounds of formula I wherein m, R, Rand Rto Rare as defined in the specification, m, is 1, 2 or 3 and X is O or a direct bond, and the corresponding unphosporylated compounds have interesting properties, e.g. immunosuppressive properties.

2-amino-propanol derivatives

Diazacycloalkanedione derivatives

Growing community of inventors

Basel, Switzerland

Rainer Albert